OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-17	20.00 ¥	+5.26%	159,589,500
26-06-16	19.00 ¥	-5.00%	134,397,500
26-06-15	20.00 ¥	+5.26%	142,823,300
26-06-12	19.00 ¥	0.00%	108,079,900
26-06-11	19.00 ¥	0.00%	101,358,000

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-17 EDT			5-day change	1st Jan Change
20.00 ^JPY	+5.26%		+5.26%	-

25-06-23	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-04-27	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI

Market Cap	8.06B 50.21M 43.27M 39.85M 37.41M 70.24M 4.75B 70.98M 471M 183M 2.32B 188M 184M	P/E 2024	-3.3x	P/E 2025	-8.97x
Enterprise Value	7.22B 45.02M 38.8M 35.73M 33.54M 62.98M 4.26B 63.64M 422M 164M 2.08B 169M 165M	EV / Sales 2024	6.27x	EV / Sales 2025	9.03x
Free-Float	88.29%	Yield 2024 *	-	Yield 2025	-

25-06-23	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-04-27	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI
25-04-09	OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding	CI
24-04-29	Poland's Tusk calls prosecutor over potential Orlen scandal	RE
24-04-21	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	CI
24-04-04	OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor	CI
23-09-18	OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index	CI
23-05-12	OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
23-04-09	OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding	CI
23-03-23	OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding	CI
21-04-27	OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
21-04-11	OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
19-01-14	OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.	CI

24-05-14	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
23-12-05	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
22-09-12	OncoTherapy Science : Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer	PU
20-10-01	OncoTherapy Science : Japanese bio-venture starts development of COVID-19 peptide vaccine	AQ

OncoTherapy Science, Inc. Stock

Stocks

4564

JP3202150003

Biotechnology & Medical Research

Valuation: OncoTherapy Science, Inc.

Chart: OncoTherapy Science, Inc.

Latest news : OncoTherapy Science, Inc.

Press Releases: OncoTherapy Science, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: OncoTherapy Science, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 day	+5.26%
1 week	+5.26%
Current month	-4.76%
3 months	-13.04%
6 months	-4.76%

1 week	18	20
1 month	18	23
Current year	18	34
1 year	18	35
3 years	15	64
5 years	15	126
10 years	15	338

Manager	Title	Age	Since
Junichi Shimada PSD	President	65	2022-06-30
Zehyon Paku PSD	President	50	2019-12-04
Yuka Yamane CTO	Chief Tech/Sci/R&D Officer	53	2012-07-31

Director	Title	Age	Since
Yuichi Komine BRD	Director/Board Member	54	2014-08-31
Zehyon Paku BRD	Director/Board Member	50	2018-05-31
Hatsuo Kato CHM	Chairman	82	2020-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCOTHERAPY SCIENCE, INC.	+5.26%	+5.26%	-13.04%	-54.55%	45.43M
ARGENX SE	+1.77%	+0.80%	+62.67%	+113.58%	54.54B
WUXI APPTEC CO., LTD.	-1.22%	+5.01%	+43.38%	+36.69%	43.86B
BIONTECH SE	+2.66%	+5.00%	-13.82%	-17.72%	22.63B
INSMED INCORPORATED	+0.86%	+3.71%	-4.98%	+371.47%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	+0.54%	+16.19%	-36.06%	15.84B
GENMAB A/S	+4.10%	-0.06%	+11.52%	-39.17%	14.83B
EXELIXIS, INC.	-0.23%	-0.40%	+26.64%	+176.50%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.17%	+0.50%	+21.80%	-	12.66B
MADRIGAL PHARMACEUTICALS, INC.	-1.35%	+6.13%	+78.90%	+103.77%	11.56B
Average	+0.59%	+0.16%	+22.92%	+72.72%	20.98B
Weighted average by Cap.	+0.40%	+0.18%	+32.74%	+88.53%

	2024	2025
Net sales	610M 3.8M 3.28M 3.02M 2.83M 5.32M 359M 5.37M 35.65M 13.89M 176M 14.27M 13.96M	750M 4.67M 4.03M 3.71M 3.48M 6.54M 442M 6.61M 43.83M 17.08M 216M 17.54M 17.17M
Net income	-1.29B -8.03M -6.92M -6.37M -5.98M -11.23M -759M -11.35M -75.28M -29.33M -372M -30.13M -29.49M	-815M -5.08M -4.38M -4.03M -3.78M -7.11M -480M -7.18M -47.63M -18.56M -235M -19.06M -18.66M
Net Debt	-527M -3.28M -2.83M -2.61M -2.45M -4.59M -311M -4.64M -30.8M -12M -152M -12.33M -12.06M	-833M -5.19M -4.47M -4.12M -3.87M -7.26M -491M -7.34M -48.68M -18.97M -240M -19.48M -19.07M